Market research
1AD.AU AdAlta Limited
AU AUD Healthcare
Latest close
As of 28 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.14
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000001AD2
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.14
About
About AdAlta Limited
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
Research context
AdAlta Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 1AD.AU discussion.
5 years, 6 months ago
AdAlta Limited is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.
From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 44.8.
AdAlta Limited's total revenue rose by 99.5% to $806K since the same quarter in the previous year.
Its net income has increased by 24.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 74.5% to $-399K since the same quarter in the previous year.
Based on the above factors, AdAlta Limited gets an overall score of 4/5.